Tagged as: Janssen. Celltrion

Celltrion Moves for Summary Judgment in Janssen v. Celltrion

Last week, in the ongoing Janssen v. Celltrion litigation concerning Celltrion’s Inflectra®, a biosimilar of Janssen’s Remicade® (infliximab), Judge Wolf of the U.S. District Court for the District of Massachusetts granted Defendants’ unopposed motion for leave to file a motion for summary judgment and accompanying briefing schedule.  In their summary judgment brief, filed on…

Read More